source
- Processa Pharma acquires Vidya Therapeutics, gaining oral BTK inhibitor VT-7208Processa Pharmaceuticals announced an all‑stock acquisition of Vidya Therapeutics, a Florida biotech developing an oral BTK inhibitor called VT‑7208. VT‑7208 is being positioned as a next‑generati…
- Prolonged hospital stays leave children isolated, urging changeAn author visiting a pediatric ward describes a young, nonverbal child with severe developmental delays who has been waiting months for a life-saving liver transplant. The child lies in a stark, ma…